AVROBIO Revenue and Competitors
Estimated Revenue & Valuation
- AVROBIO's estimated annual revenue is currently $21.2M per year.
- AVROBIO's estimated revenue per employee is $331,797
- AVROBIO's total funding is $85M.
Employee Data
- AVROBIO has 64 Employees.
- AVROBIO grew their employee count by -36% last year.
AVROBIO's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Chief Staff | Reveal Email/Phone |
2 | VP , Human Resources | Reveal Email/Phone |
3 | VP Information Technology | Reveal Email/Phone |
4 | VP, Clinical Development Operations | Reveal Email/Phone |
5 | VP Program Lead, Gaucher Franchise | Reveal Email/Phone |
6 | VP Clinical Development | Reveal Email/Phone |
7 | VP, Global Manufacturing and Supply Chain | Reveal Email/Phone |
8 | Head Biostatistics | Reveal Email/Phone |
9 | Executive Assistant To Chief Medical Officer | Reveal Email/Phone |
10 | Chief Legal Officer | Reveal Email/Phone |
AVROBIO Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $5.2M | 67 | -45% | $107.3M | N/A |
#2 | $0.3M | 2 | 0% | N/A | N/A |
#3 | $5.1M | 33 | 6% | N/A | N/A |
#4 | $11.9M | 77 | -37% | $312.8M | N/A |
#5 | $0.9M | 6 | 0% | N/A | N/A |
#6 | $235M | 300 | -5% | $340.9M | N/A |
#7 | $45.9M | 237 | -7% | $7.6M | N/A |
#8 | $3.9M | 50 | 35% | N/A | N/A |
#9 | $5.4M | 35 | 3% | N/A | N/A |
#10 | $1.6M | 10 | 0% | N/A | N/A |
What Is AVROBIO?
Clinical stage company focused on delivering step-change cell & gene therapies targeting cancer and rare disease.
keywords:N/A
$85M
Total Funding
64
Number of Employees
$21.2M
Revenue (est)
-36%
Employee Growth %
N/A
Valuation
N/A
Accelerator
AVROBIO News
2022-04-20 - Analysts Anticipate AVROBIO, Inc. (NASDAQ:AVRO) Will Post ...
Analysts Anticipate AVROBIO, Inc. (NASDAQ:AVRO) Will Post Earnings of -$0.58 Per Share. Posted by admin on Apr 24th, 2022.
2022-04-17 - Is Avrobio Inc (AVRO) Stock at the Top of the Biotechnology Industry?
Avrobio Inc (AVRO) is around the middle of the Biotechnology industry according to InvestorsObserver. AVRO received an overall rating of 37,...
2022-04-06 - AVROBIO, Inc. (NASDAQ:AVRO) Receives $7.84 Average ...
AVROBIO, Inc. (NASDAQ:AVRO) Receives $7.84 Average Price Target from Analysts. Posted by admin on Apr 12th, 2022.
Other Companies in Cambridge
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | N/A | 64 | 0% | N/A |
#2 | $8.1M | 64 | -22% | N/A |
#3 | $15.6M | 64 | -9% | N/A |
#4 | $8.4M | 64 | 8% | N/A |
#5 | $8.1M | 64 | -11% | $55.9M |